Intracellular Th Stock Today
| ITCI Stock | USD 85.64 2.29 2.75% |
Performance8 of 100
| Odds Of DistressLess than 35
|
Intracellular is trading at 85.64 as of the 21st of November 2024. This is a 2.75 percent increase since the beginning of the trading day. The stock's open price was 83.35. Intracellular has about a 35 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Note, on July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Intracellular Th's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of January 2014 | Category Healthcare | Classification Health Care |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. The company has 106.02 M outstanding shares of which 2.36 M shares are currently shorted by private and institutional investors with about 4.1 trading days to cover. More on Intracellular Th
Moving against Intracellular Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Intracellular Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Sharon Mates | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIntracellular can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Intracellular's financial leverage. It provides some insight into what part of Intracellular's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intracellular Th (ITCI) is traded on NASDAQ Exchange in USA. It is located in 430 East 29th Street, New York, NY, United States, 10016 and employs 610 people. Intracellular is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.08 B. Intracellular Th conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 106.02 M outstanding shares of which 2.36 M shares are currently shorted by private and institutional investors with about 4.1 trading days to cover.
Intracellular Th currently holds about 628.74 M in cash with (124.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.64.
Check Intracellular Probability Of Bankruptcy
Ownership AllocationIntracellular Th has a total of 106.02 Million outstanding shares. The majority of Intracellular Th outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intracellular to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intracellular Th. Please pay attention to any change in the institutional holdings of Intracellular Th as this could imply that something significant has changed or is about to change at the company. On July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Intracellular Th's common stock.
Check Intracellular Ownership Details
Intracellular Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Clearbridge Advisors, Llc | 2024-06-30 | 1.7 M | |
| Geode Capital Management, Llc | 2024-06-30 | 1.7 M | |
| Perceptive Advisors Llc | 2024-09-30 | 1.6 M | |
| Deep Track Capital, Lp | 2024-09-30 | 1.6 M | |
| Franklin Resources Inc | 2024-06-30 | 1.6 M | |
| Suvretta Capital Management, Llc | 2024-06-30 | 1.6 M | |
| Holocene Advisors, Lp | 2024-06-30 | 1.5 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 1.4 M | |
| Alyeska Investment Group, L.p. | 2024-06-30 | 1.4 M | |
| Fmr Inc | 2024-09-30 | 11.1 M | |
| Vanguard Group Inc | 2024-09-30 | 9.6 M |
Intracellular Historical Income Statement
Intracellular Stock Against Markets
Intracellular Corporate Management
| CPA CPA | CFO, Fin | Profile | |
| Suresh MD | Executive Officer | Profile | |
| Karen Esq | Senior Officer | Profile | |
| Willie MD | Senior Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.